Management of Hepatitis C Infection
Summary
- Glecaprevir is an NS3/NS4A protease inhibitor
- Glecaprevir, coformulated with pibrentasvir, is approved by the FDA and the EMA for first-line treatment of patients infected with genotypes 1-6 HCV[FDA Glecaprevir Pibrentasvir; EMA Glecaprevir Pibrentasvir]
- Some treatment-experienced patients are also eligible for treatment with this coformulation, depending on the type of agent previously used and HCV genotype
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment